Soranus Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-12-2024
- Paid Up Capital ₹ 0.10 M
as on 09-12-2024
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -62.85%
(FY 2019)
- Profit -602.80%
(FY 2019)
- Ebitda 20.59%
(FY 2019)
- Net Worth -13.93%
(FY 2019)
- Total Assets -10.97%
(FY 2019)
About Soranus Lifesciences
The Corporate was formerly known as Claritas Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Manan Bhatt, Navin Bhatt, and Lokesh Khandelwal serve as directors at the Company.
- CIN/LLPIN
U24230GJ2011PTC067578
- Company No.
067578
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Oct 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Soranus Lifesciences Private Limited offer?
Soranus Lifesciences Private Limited offers a wide range of products and services, including Respiratory System Drugs, Anti Asthma Drug, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Soranus Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manan Bhatt  | Director | 20-Jul-2015 | Current |
| Navin Bhatt | Director | 13-Oct-2015 | Current |
| Lokesh Khandelwal | Director | 13-Oct-2015 | Current |
Financial Performance of Soranus Lifesciences.
Soranus Lifesciences Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 62.85% decrease. The company also saw a substantial fall in profitability, with a 602.8% decrease in profit. The company's net worth observed a substantial decline by a decrease of 13.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Soranus Lifesciences?
In 2019, Soranus Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eujen Lifesciences Private LimitedActive 12 years 2 monthsManan Bhatt and Navin Bhatt are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Soranus Lifesciences?
Soranus Lifesciences has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Soranus Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Soranus Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
